Toll-like receptors: Emerging targets of immunomodulation

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 1, 2004, Pages 85-100

  Quesniaux, Valerie F J ^a   Ryffel, Bernhard ^a  

^a CNRS   (France)

Author keywords

Allergy; Cancer; IL IR; Infection; Inflammation; Toll like receptor (TLR); Vaccine

Indexed keywords

BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; BROPIRIMINE; CYCLOPEPTIDE; DOUBLE STRANDED RNA; E 5531; ENDOTOXIN; FLAGELLIN; HP 206; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; LIPID A; LIPID A DERIVATIVE; LIPOPROTEIN; LIPOTEICHOIC ACID; LOXORIBINE; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OM 174; PACLITAXEL; PEPTIDOGLYCAN; PICIBANIL; RESIQUIMOD; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS PROTEIN;

ALLERGIC DISEASE; ASTHMA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CANCER; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; CPG ISLAND; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENTERITIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION CONTROL; INFLAMMATORY DISEASE; MOLECULAR RECOGNITION; NONHUMAN; PRION DISEASE; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; VACCINATION; VIRUS INFECTION;

EID: 0347286806     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.1.85     Document Type: Review

References (138)

1. MEDZHITOV R, JANEWAY CA Jr: Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. (1997) 9:4-9.
2. MEDZHITOV R, PRESTON-HURLBURT P, JANEWAY CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 388:394-397.
3. LEMAITRE B, REICHHART JM, HOFFMANN JA: Drosophila host defense: differential induction of antimicrobial peptide genes after infection by various classes of microorganisms. Proc. Natl Acad. Sci. USA (1997) 94:14614-14619.
4. LEMAITRE B, NICOLAS E, MICHAUT L, REICHHART JM, HOFFMANN JA: The dorsoventral regulatory gene cassette spitzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86:973-983.
5. AKIRA S: Mammalian Toll-like receptors. Curr. Opin. Immunol. (2003) 15:5-11.
6. MEDZHITOV R, BIRON CA: Innate immunity. Curr. Opin. Immunol. (2003) 15:2-4.
7. MEDZHITOV R: Toll-like receptors and innate immunity Nat. Rev. Immunol. (2001) 1:135-145.
8. UNDERHILL DM: Toll-like receptors: networking for success. Eur. J. Immunol. (2003) 33:1767-1775.
9. STENGER S, MODLIN RL: Control of Mycobacterium tuberculosis through mammalian Toll-like receptors. Curr. Opin. Immunol. (2002) 14:452-457.
10. MUZIO M, BOSISIO D, POLENTARUTTI N et al.: Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. (2000) 164:5998-6004.
11. SCHNARE M, BARTON GM, HOLT AC, TAKEDA K, AKIRA S, MEDZHITOV R: Toll-like receptors control activation of adaptive immune responses. Nat Immunol. (2001) 2:947-950.
12. THOMA-USZYNSKI S, STENGER S, TAKEUCHI O et al.: Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science (2001) 291:1544-1547.
13. ALIPRANTIS AO, YANG RB, MARK MR et al.: Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor 2. Science (1999) 285:736-739.
14. MEANS TK, JONES BW, SCHROMM AB et al.: Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J. Immunol. (2001)166:4074-4082.
15. AKIRA S, YAMAMOTO M, TAKEDA K: Role of adapters in Toll-like receptor signalling. Biochem. Soc. Trans. (2003) 31:637-642.
16. HORNG T, BARTON GM, FLAVELL RA, MEDZHITOV R: The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature (2002) 420:329-333.
17. YAMAMOTO M, SATO S, HEMMI H et al.: Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature (2002) 420:324-329.
18. O'NEILL LA, FITZGERALD KA, BOWIE AG: The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. (2003) 24:286-289.
19. OSHIUMI H, MATSUMOTO M, FUNAMI K, AKAZAWA T, SEYA T: TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol. (2003) 4:161-167.
20. YAMAMOTO M, SATO S, MORI K et al.: Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol. (2002) 169:6668-6672.
21. YAMAMOTO M, SATO S, HEMMI H et al.: Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science (2003). (E published ahead of print).
22. PICARD C, PUEL A, BONNET M et al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science (2003) 299:2076-2079.
23. KOBAYASHI K, HERNANDEZ LD, GALAN JE, JANEWAY CA Jr, MEDZHITOV R, FLAVELL RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 110:191-202.
24. SUZUKI N, SUZUKI S, DUNCAN GS et al.: Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 Nature (2002) 416:750-756.
25. JANSSENS S, BEYAERT R: Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell (2003) 11:293-302.
26. O'NEILL LA: SIGIRR puts the brakes on Toll-like receptors. Nat. Immunol. (2003) 4:823-824.
27. WALD D, QIN J, ZHAO Z et al.: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. (2003) 4:920-927.
28. TAILLEUX L, SCHWARTZ O, HERRMANN JL et al.: DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. (2003) 197:121-127.
29. MAEDA N, NIGOU J, HERRMANN JL et al.: The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan. J. Biol. Chem. (2003) 278: 5513-5516.
30. GEIJTENBEEK TB, VAN VLIET SJ, KOPPEL EA et al.: Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. (2003) 197:7-17.
31. LEE SJ, ZHENG NY, CLAVIJO M, NUSSENZWEIG MC: Normal host defense during systemic candidiasis in mannose receptor-deficient mice. Infect. Immun. (2003) 71:437-445.
32. LEE SJ, EVERS S, ROEDER D et al.: Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science (2002) 295:1898-1901.
33. PLATT N, HAWORTH R, DARLEY L, GORDON S: The many roles of the class A macrophage scavenger receptor. Int. Rev. Cytol. (2002) 212:1-40.
34. PEISER L, DE WINTHER MP, MAKEPEACE K et al.: The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses. Infect. Immun. (2002) 70:5346-5354.
35. PLATT N, SUZUKI H, KURIHARA Y, KODAMA T, GORDON S: Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Proc. Natl Acad. Sci. USA (1996) 93:12456-12460.
36. BROWN GD, HERRE J, WILLIAMS DL, WILLMENT JA, MARSHALL AS, GORDON S: Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med. (2003) 197:1119-1124.
37. GANTNER BN, SIMMONS RM, CANAVERA SJ, AKIRA S, UNDERHILL DM: Collaborative induction of inflammatory responses by dectin-1 and Toll-like Receptor 2. J. Exp. Med. (2003) 197:1107-1117.
38. BEUTLER B: TLR4 as the mammalian endotoxin sensor. Curr. Top. Microbiol. Immunol. (2002) 270:109-120.
39. MEANS TK, LIEN E, YOSHIMURA A, WANG S, GOLENBOCK DT, FENTON MJ: The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J. Immunol. (1999) 163:6748-6755.
40. POLTORAK A, HE X, SMIRNOVA I et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282:2085-2088.
41. TAKEUCHI O, HOSHINO K, KAWAI T et al.: Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity (1999) 11:443-451.
42. SEKI E, TSUTSUI H, TSUJI NM et al.: Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J Immunol. (2002) 169:3863-3868.
43. EDELSON BT, UNANUE ER: MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J. Immunol. (2002) 169:3869-3875.
44. YANG KK, DORNER BG, MERKEL U et al.: Neutrophil influx in response to a peritoneal infection with Salmonella is delayed in lipopolysaccharide-binding protein or CD14-deficient mice. J. Immunol. (2002) 169:4475-4480.
45. BIHL F, SALEZ L, BEAUBIER M et al.: Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J. Immunol. (2003) 170:6141-6150.
46. HAYASHI F, SMITH KD, OZINSKY A et al.: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 410:1099-1103.
47. ABEL B, THIEBLEMONT N, QUESNIAUX VJ et al.: Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J. Immunol. (2002) 169:3155-3162.
48. REILING N, HOLSCHER C, FEHRENBACH A et al.: Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J. Immunol. (2002) 169:3480-3484.
49. JONES BW, MEANS TK, HELDWEIN KA et al.: Different Toll-like receptor agonists induce distinct macrophage responses. J. Leukoc. Biol. (2001) 69:1036-1044.
50. GILLERON M, QUESNIAUX VF, PUZO G: Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette-Guerin and Mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response. J. Biol. Chem. (2003). (E published ahead of print).
51. ALEXOPOULOU L, HOLT AC, MEDZHITOV R, FLAVELL RA: Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature (2001) 413:732-738.
52. BIEBACK K, LIEN E, KLAGGE IM et al.: Hemagglutinin protein of wild-type measles virus activates Toll-like receptor 2 signaling. J. Virol. (2002) 76:8729-8736.
53. HAEBERLE HA,TAKIZAWA R, CASOLA A et al.: Respiratory syncytial virus-induced activation of nuclear factor-κB in the lung involves alveolar macrophages and Toll-like receptor 4-dependent pathways. J. Infect. Dis. (2002) 186:1199-1206.
54. BAFICA A, SCANGA CA, SCHITO ML, HIENY S, SHER A: Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2. J. Immunol. (2003) 171:1123-1127.
55. LEBRON F, VASSALLO R, PURI V, LIMPER AH: Pneumocystis carinii cell wall β-glucans initiate macrophage inflammatory responses through NF-kB activation. J. Biol. Chem. (2003).
56. NETEA MG, VAN DER GRAAF CA, VONK AG, VERSCHUEREN I, VAN DER MEER JW, KULLBERG BJ: The role of Toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. (2002) 185:1483-1489.
57. SCANGA CA, ALIBERTI J, JANKOVIC D et al.: Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J. Immunol. (2002) 168:5997-6001.
58. ALIBERTI J, VALENZUELA JG, CARRUTHERS VB et al.: Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat. Immunol. (2003) 4:485-490.
59. COELHO PS, KLEIN A, TALVANI A et al.: Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-γ-primed-macrophages. J. Leukoc. Biol. (2002) 71:837-844.
60. MAGEZ S, STIJLEMANS B, BARAL T, DE BAETSELIER P: VSG-GPI anchors of African trypanosomes: their role in macrophage activation and induction of infection-associated immunopathology. Microbes Infect. (2002) 4:999-1006.
61. ADACHI K, TSUTSUI H, KASHIWAMURA S et al.: Plasmodium berghei infection in mice induces liver injury by an IL-12- and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J. Immunol. (2001) 167:5928-5934.
62. BULUT Y, FAURE E, THOMAS L et al.: Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J. Immunol. (2002) 168:1435-1440.
63. COSTA CP, KIRSCHNING CJ, BUSCH D et al.: Role of chlamydial heat shock protein 60 in die stimulation of innate immune cells by Chlamydia pneumoniae. Eur. J. Immunol. (2002) 32:2460-2470.
64. VABULAS RM, AHMAD-NEJAD P, GHOSE S, KIRSCHNING CJ, ISSELS RD,WAGNER H: Hsp 70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem. (2002) 277:15107-15112.
65. KIRSCHNING CJ, SCHUMANN RR: TLR2: cellular sensor for microbial and endogenous molecular patterns. Curr. Top. Microbiol. Immunol. (2002) 270:121-144.
66. ASEA A, REHLI M, KABINGU E et al.: Novel signal transduction pathway utilized by extracellular Hsp70: role of Toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. (2002) 277:15028-15034.
67. HABICH C, BAUMGART K, KOLB H, BURKART V: The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J. Immunol. (2002) 168:569-576.
68. BAUSINGER H, LIPSKER D, ZIYLAN U et al.: Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur. J. Immunol. (2002) 32:3708-3713.
69. AOSAI F, CHEN M, KANG HK et al.: Toxoplasma gondii-derived heat shock protein Hsp70 functions as a B cell mitogen. Cell Stress Chaperones (2002) 7:357-364.
70. TSUTSUMI-ISHII Y, NAGAOKA I: Modulation of human β-defensin-2 transcription in pulmonary epithelial cells by lipopolysaccharide-stimulated mononuclear phagocytes via proinflammatory cytokine production. J. Immunol. (2003) 170:4226-4236.
71. BIRAGYN A, RUFFINI PA, LEIFER CA et al.: Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science (2002) 298:1025-1029.
72. TERMEER C, BENEDIX F, SLEEMAN J et al.: Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med. (2002) 195:99-111.
73. TERMEER C, SLEEMAN JP, SIMON JC: Hyaluronan - magic glue for the regulation of the immune response? Trends Immunol. (2003) 24:112-114.
74. TEDER P, VANDIVIER RW et al.: Resolution of lung inflammation by CD44. Science (2002) 296:155-158.
75. MATZINGER P: The danger model: a renewed sense of self. Science (2002) 296:301-305.
76. ULEVITCH RJ, TOBLAS PS: Recognition of Gram-negative bacteria and endotoxin by the innate immune system. Curr. Opin. Immunol. (1999) 11:19-22.
77. KAWAI T, TAKEUCHI O, FUJITA T et al.: Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. (2001) 167:5887-5894.
78. MUTA T, TAKESHIGE K: Essential roles of CD14 and lipopolysaccharide-binding protein for activation of Toll-like receptor (TLR)2 as well as TLR4 Reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations. Eur. J. Biochem. (2001) 268:4580-4589.
79. SCHRODER NW, MORATH S, ALEXANDER C et al.: Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. (2003) 278:15587-15594.
80. OGAWA T, ASAI Y, SAKAI Y et al.: Endotoxic and immunobiological activities of a chemically synthesized lipid A of Helicobacter pylori strain 206-1. FEMS Immunol. Med. Microbiol. (2003) 36:1-7.
81. LAGADEC P, RAYNAL S, LIEUBEAU B et al.: Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-β1 in tumor cells. Implications for tumor development. Am. J. Pathol. (1999) 154:1867-1876.
82. ONIER N, HILPERT S, REVENEAU S et al.: Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats Int. J. Cancer. (1999) 81:755-760.
83. ONIER N, HILPERT S, ARNOULD L et al.: Cure of.colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin. Exp. Metastasis. (1999) 17:299-306.
84. THOMA-USZYNSKI S, KIERTSCHER SM, OCHOA MT et al.: Activation of Toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J. Immunol. (2000) 165:3804-3810.
85. TAKEUCHI O, KAWAI T, MUHLRADT PF et al.: Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol. (2001) 13:933-940.
86. MORR M, TAKEUCHI O, AKIRA S, SIMON MM, MUHLRADT PF: Differential recognition of structural details of bacterial lipopeptides by Toll-like receptors. Eur. J. Immunol. (2002) 32:3337-3347.
87. TAKEUCHI O, SATO S, HORIUCHIT SR et al.: Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. (2002) 169:10-14.
88. MCCURDY JD, OLYNYCH TJ, MAHER LH, MARSHALL JS: Cutting edge: distinct Toll like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. (2003) 170:1625-1629.
89. CHAMAILLARD M, HASHIMOTO M, HORIE Y et al.: An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid Nat. Immunol. (2003) 4:702-707.
90. ROETHLISBERGER P, IIDA-TANAKA N, HOLLEMEYER K, HEINZLE E, ISHIZUKA I, FISCHER W: Unique poly(glycerophosphate) lipoteichoic acid and the glycolipids of a Streptococcus sp. closely related to Streptococcus pneumoniae. Eur. J. Biochem. (2000) 267:5520-5530.
91. SCHWARZ K, STORNI T MANOLOVA V et al.: Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. (2003) 33:1465-1470.
92. MEANS TK, HAYASHI F, SMITH KD, ADEREM A, LUSTER AD: The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. (2003) 170:5165-5175.
93. MIZEL SB, HONKO AN, MOORS MA, SMITH PS, WEST AP: Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J. Immunol. (2003) 170:6217-6223.
94. HEMMI H, TAKEUCHI O, KAWAI T et al.: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740-745.
95. BANDHOLTZ L, GUO Y, PALMBERG C et al.: Hsp90 binds CpG oligonucleotides directly: implications for Hsp90 as a missing link in CpG signaling and recognition. Cell Mol. Life Sci. (2003) 60:422-429.
96. KAWASAKI K, NOGAWA H, NISHIJIMA M: Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis. J. Immunol. (2003) 170:413-420.
97. WANG J, KOBAYASHI M, HAN M et al.: MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-α expression in human myelomonocytic cells. Br. J. Haematol. (2002) 118:638-645.
98. PERERA PY, MAYADAS TN, TAKEUCHI O et al.: CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J. Immunol. (2001) 166:574-581.
99. HEMMI H, KAISHO T, TAKEUCHI O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. (2002) 3:196-200.
100. CAR BD, ENG VM, SCHNYDER B et al.: Role of interferon-γ in intedeukin 12-induced pathology in mice Am. J. Pathol. (1995) 147:1693-1707.
101. GUTIERREZ-RAMOS JC, BLUETHMANN H: Molecules and mechanisms operating in septic shock: lessons from knockout mice. Immunol. Today (1997) 18:329-334.
102. BEUTLER B: Innate immune sensing of microbial infection: the mechanism and the therapeutic challenge. Wien Med. Wochenschr. (2002) 152:547-551.
103. BEUTLER B: Endotoxin antagonism: conceptual basis and therapeutic potential. Expert Opin. Ther. Targets (2002) 6:147-158.
104. WEIGHARDT H, KAISER-MOORE S, VABULAS RM, KIRSCHNING CJ, WAGNER H, HOLZMANN B: Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J. Immunol. (2002) 169:2823-2827.
105. ULEVITCH RJ: New therapeutic targets revealed through investigations of innate immunity. Crit. Care Med. (2001) 29:S8-12.
106. CALANDRA T, BOCHUD PY, HEUMANN D: Cytokines in septic shock. Curr. Clin. Top. Infect. Dis. (2002) 22:1-23.
107. ROGER T, DAVID J, GLAUSER MP, CALANDRA T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature (2001) 414:920-924.
108. +) T cells and could be an efficient vaccine target. J. Immunol. (2003) 171:32-36.
109. KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760.
110. GILLIET M, BOONSTRA A et al.: The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. (2002) 195:953-958.
111. HARTE MT, HAGA IR, MALONEY G et al.: The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. (2003) 197:343-351.
112. MURABAYASHI N, KURITA-TANIGUCHI M, AYATA M, MATSUMOTO M, OGURA H, SEYA T: Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of Toll stimulators in DC maturation and MV amplification. Microbes Infect. (2002) 4:785-794.
113. +) dendritic cells. J. Exp. Med. (2002) 196:1415-1425.
114. ALCAMI A: Structural basis of the herpesvirus M3-chemokine interaction. Trends Microbiol. (2003) 11:191-192.
115. ALCAMI A: Viral mimicry of cyrokines, chemokines and their receptors. Nat. Rev. Immunol. (2003) 3:36-50.
116. HUBEAU C, SINGER M, LAGRANDERIE M, MARCHAL G, VARGAFTIG B: Extended freeze-dried Mycobacterium bovis Bacillus Calmette-Guerin induces the release of interleukin-12 but not tumour necrosis factor-α by alveolar macrophages, both in vitro and in vivo. Clin. Exp. Allergy. (2003) 33:386-393.
117. KRIEG AM: CpG motifs: the active ingredient in bacterial extracts? Nat. Med. (2003) 9:831-835.
118. VON HERRATH MG, BOT A: Immune responsiveness, tolerance and dsRNA: implications for traditional paradigms. Trends Immunol. (2003) 24:289-292.
119. OKAMOTO M, SATO M: Toll-like receptor signaling in anti-cancer immunity. J. Med. Invest. (2003) 50:9-24.
120. MELIEF CJ, VAN DER BURG SH, TOES RE, OSSENDORP F, OFFRINGA R: Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. (2002) 188:177-182.
121. LEADBETTER EA, RIFKIN IR, HOHLBAUM AM, BEAUDETTE BC, SHLOMCHIK MJ, MARSHAK-ROTHSTEIN A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 416:603-607.
122. RIFKIN IR, MARSHAK-ROTHSTEIN A: T-bet: the Toll-bridge to class-switch recombination? Nat. Immunol. (2003) 4:650-652.
123. FELDMANN M, MAINI RN: Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol. (2001) 19:163-196.
124. SEIBL R, BIRCHLER T, LOELIGER S et al.: Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. (2003) 162:1221-1227.
125. KYBURZ D, RETHAGE J, SEIBL R et al.: Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by Toll-like receptor signaling. Arthritis Rheum. (2003) 48:642-650.
126. CHOE JY, CRAIN B, WU SR, CORR M: Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J. Exp. Med. (2003) 197:537-542.
127. HERRICK CA, BOTTOMLY K: To respond or not to respond: T cells in allergic asthma. Nat. Rev. Immunol. (2003) 3:405-412.
128. EISENBARTH SC, PIGGOTT DA, HULEATT JW, VISINTIN I, HERRICK CA, BOTTOMLY K: Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell Type 2 responses to inhaled antigen. J. Exp. Med. (2002) 196:1645-1651.
129. LAGRANDERIE M, NAHORI MA, BALAZUC AM et al.: Dendritic cells recruited to the lung shortly after intranasal delivery of Mycobacterium bovis BCG drive the primary immune response towards a Type 1 cytokine production. Immunology (2003) 108:352-364.
130. LIU N, OHNISHI N, NI L, AKIRA S, BACON KB: CpG directly induces T-bet expression and inhibits Ig(γ1) and Ig(epsilon) switching in B cells. Nat. Immunol. (2003).
131. ORTEGA-CAVA CF, ISHIHARA S, RUMI MA et al.: Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J. Immunol. (2003) 170:3977-3985.
132. OTTE JM, ROSENBERG IM, PODOLSKY DK: Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology (2003) 124:1866-1878.
133. ZEUKE S, ULMER AJ, KUSUMOTO S, KATUS HA, HEINE H: TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc. Res. (2002) 56:126-134.
134. LAMAN JD, SCHONEVELD AH, MOLL FL, VAN MEURS M, PASTERKAMP G: Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques. Am. J. Cardiol. (2002) 90:119-123.
135. BOEKHOLDT SM, AGEMA WR, PETERS RJ et al.: Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation (2003) 107:2416-2421.
136. HOLMLUND L, CORTES TORO V, IVERFELDT K: Additive effects of amyloidβ fragment and interleukin-1β on interleukin-6 secretion in rat primary glial cultures. Int. J. Mol. Med.. (2002) 10:245-250.
137. REINDL M, LUTTEROTTI A, INGRAM J et al.: Mutations in the gene for Toll-like receptor 4 and multiple sclerosis. Tissue Antigens. (2003) 61:85-88.
138. PRINZ M, HEIKENWALDER M, SCHWARZ P, TAKEDA K, AKIRA S, AGUZZI A: Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep. (2003) 4:195-199.